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The epidermal growth factor receptor (EGFR 
or ERBB1), is aberrantly activated in many human 
malignancies , including colorectal cancer, non-small cell 
lung cancer, and head and neck squamous cell carcinoma 
(HNSCC). In these diseases, overexpression correlates 
with poor survival. Inhibitors of EGFR signaling, both 
monoclonal antibodies (cetuximab, panitumumab) and 
tyrosine  kinase  inhibitors  (TKIs;  erlotinib,  gefitinib), 
demonstrate activity in these cancers, but responses are 
heterogeneous. Resistance to EGFR-inhibiting agents 
continues to pose a substantial obstacle to their effective 
use. Many tumors do not initially respond, indicative of 
intrinsic resistance; of those responding, most eventually 
progress, demonstrating acquired resistance. In the 
treatment of HNSCC, cetuximab, in combination with 
radiation therapy, achieves substantial rates of response[1]. 
However, the response rate to single-agent cetuximab is 
only 10-15%; to erlotinib, 5%[2, 3]. Molecular predictors 
of response to EGFR inhibition in HNSCC remain poorly 
defined. 
Several determinants of response to EGFR 
inhibitors have been characterized in lung and colorectal 
cancer. In lung cancer, molecular determinants were 
presaged  by  the  realization  that  a  specific  clinically-
definedsubpopulation  (Asian,  female,  never-smokers, 
adenocarcinomas) responded best to TKIs.  Subsequently, 
EGFR mutations associated with TKI sensitivity (exon 
19 and L858R) or resistance (T790M) were identified[4]. 
In colorectal cancer, KRAS mutations were found to be 
associated with cetuximab resistance[5].  In both lung 
and colorectal cancers, EGFR copy number predicts 
response to cetuximab somewhat, but the predictive value 
is not high. Although not yet in clinical use, preclinical 
data has also implicatedresistance mechanisms such as 
VEGF  signaling, AKT/mTOR  pathway  activation,  and 
“oncogenic shift” to other receptor tyrosine kinases such 
as ERBB2, ERBB3, MET or IGF-1R, via overexpression 
or increased ligand availability[6].
In contrast, our understanding of mechanisms 
underpinning resistance to EGFR-targeted therapy is 
comparatively poor in HNSCC. Molecular determinants 
are  not  well  defined.  The  most  predictive  factor  for 
cetuximab sensitivity in HNSCC is a clinical finding – the 
development of a skin rash during treatment[1]. EGFR 
copy  number  is  not  predictive  of  response. Activating 
EGFR mutations are very rare, as are KRAS and BRAF 
mutations. Unlike in some other cancers such as GBM, 
the EGFRvIII variant does not predict response. Some 
promising insights have been reported recently, however. 
Preclinical data have demonstrated that increased 
expression of the ligand heparin-binding EGF-like 
growth factor (HB-EGF) occurs during the development 
of resistance in HNSCC cell lines, and that plasma HB-
EGF levels are elevated in recurrent tumors[7]. There is 
also evidence that head and neck tumors can evade EGFR 
inhibition by undergoing epithelial-to-mesenchymal 
transition, thereby losing EGFR dependency.
Recently, frequent deletion of the PTPRS  gene, 
encoding protein tyrosine phosphatase receptor S, was 
described  in  HNSCC[8].  A  comprehensive  genome-
wide analysis of copy number alteration in HNSCC 
identified  recurrent,  intragenic  microdeletions  at  the 
PTPRS gene locus in 26% of tumors. The focal nature 
of these deletions argues that PTPRS is the target of 
copy number alteration at chromosome 19p13. These 
deletions result in loss of protein expression of PTPRS, 
a membrane-bound phosphatase that dephosphorylates 
EGFR. Depletion of PTPRS leads to increased levels 
of phosphorylated EGFRand increasedEGFR signaling. 
Interestingly, loss of PTPRS, and consequently increased 
EGFR phosphorylation, renderscancer cells significantly 
more resistant to EGFR inhibitors. In fact, in normally 
TKI-sensitive HNSCC and lung cancer cells, knockdown 
of  PTPRS  is  sufficient  to  induce  erlotinib  resistance. 
PTPRS seems to play a similar role modulating cetuximab 
resistance in HNSCC cells. Interestingly, clinical outcome 
is also dramatically influenced by PTPRS status. Patients 
with lung adenocarcinomas harboring activating EGFR 
mutations  andlow  PTPRSexpression  have  significantly 
poorer survival thansimilar patients with normal PTPRS-
expressing tumors.
Together, these recent data demonstrate that a 
frequent genetic event in HNSCC, PTPRS loss, is able 
to help drive EGFR pathway activation, and modulate 
sensitivity to EGFR inhibitors. With additional clinical 
investigation, these findings may open the door to the 
possibility of PTPRS status serving as a biomarker for 
drug resistance, analogous to EGFR or KRAS resistance 
mutations in lung and colorectal cancer. This might aid 
in triaging patients to EGFR inhibitors or conventional 
chemotherapy. TKI trials, limited to sensitive EGFR 
mutations in lung cancer, have achieved impressive 
response rates of 50-70%. Ultimately, overcoming Oncotarget 2011; 2:  894 - 895 895 www.impactjournals.com/oncotarget
these novel mechanisms of resistance in HNSCC –loss 
of PTPRS or persistent levels of EGFR activity – will 
prove instrumental in enhancing tumor response to these 
promising agents.
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